Understand the source comparison
Step 1: Identify Your Longevity Target — Cellular vs Systemic Pathways
To use peptides for longevity effectively, start by identifying which aging pathway you're addressing. Longevity isn't one mechanism. It's a cascade of interconnected processes. Cellular senescence (the accumulation of 'zombie cells' that secrete inflammatory
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- To use peptides for longevity effectively, start by identifying which aging pathway you're addressing. Longevity isn't one mechanism. It's a cascade of interconnected processes. Cellular senescence (the accumulation of 'zombie cells' that secrete inflammatory cytokines), mitochondrial dysfunction (reduced ATP production and increased reactive oxygen species), impaired autophagy (failure to clear damaged proteins), and NAD+ depletion (loss of sirtuin activity) each require different peptide interventions.
- Thymalin, for example, targets thymic regeneration and immune system aging. The thymus gland shrinks by approximately 3% per year after puberty, leading to reduced T-cell diversity and impaired pathogen clearance. Clinical research published in Immunity & Ageing found that bioregulatory peptides targeting thymic epithelial cells increased naïve T-cell populations by 18–27% in subjects over age 50. Thymalin addresses immune senescence specifically. Not mitochondrial function or autophagy.
- Epithalon (also called epithalamin) works through telomerase activation. The enzyme that adds TTAGGG repeats to chromosome ends, preventing cellular replication limits. A 2003 study in Bulletin of Experimental Biology and Medicine found epithalon increased telomerase activity by 33% in cultured human fibroblasts. This is a fundamentally different intervention than peptides targeting mTOR inhibition or AMPK activation.
- Matching peptide mechanism to aging target is where most protocols fail. Stacking MK-677 (a ghrelin mimetic that increases growth hormone pulsatility) with compounds that activate autophagy creates a biochemical conflict. Elevated IGF-1 from growth hormone suppresses autophagy through mTOR activation, while autophagy-inducing peptides work by inhibiting mTOR. The pathways oppose each other.